We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Brain Metastases Respond to Paclitaxel, Carboplatin, and Brain RT

Aug 1, 2000
Volume: 
9
Issue: 
8
  • Lung Cancer

NEW ORLEANS—In patients with brain metastases related to
non-small-cell lung cancer, adding paclitaxel (Taxol) plus
carboplatin (Paraplatin) to standard radiotherapy may increase
overall treatment efficacy, French investigators reported at the 36th
Annual Meeting of the American Society of Clinical Oncology.

The rationale for the combined treatment is based on the use of
radiotherapy as standard treatment of brain metasta-ses—although
it increases survival by less than 6 months—and recent data
suggesting that chemotherapy may also be effective in this setting.

This phase II multicenter study evaluated chemotherapy followed by
radiotherapy in 46 chemonaïve patients with inoperable brain
metastases. Patients received paclitaxel 200 mg/m² over 3 hours
and carboplatin AUC 6 on day 1 every 3 weeks. Radiotherapy 30 Gy in
10 fractions to the brain was delivered to patients who did not
respond after two to four courses of chemotherapy.

Two Courses Effective

Two courses of this regimen were considered effective and of low
toxicity, reported Gilles Robinet, MD, of the Hôpital Augustin
Morvan, Brest, France. The median number of cycles per patient was
2.5, for a total of 144 during the study.

After two cycles of chemotherapy, the effect on brain metastases
included partial response in 8 patients (18%), stable disease in 15
(36%), and progressive disease in 19 (42%) (responses were
undetermined in 2 patients).

The effects on extrabrain metastases included partial responses in 10
(22%), stable disease in 21 (47%), and progressive disease in 9 (20%)
(responses were undetermined in 5 patients).

Related Articles

  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer
  • New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition
  • Durable Responses, Longer Survival Seen in NSCLC With Nivolumab at 5 Years

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.